FDA Approves Calaspargase Pegol-mknl for Pediatric/AYA ALL

On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years.

Read the full FDA press release here.

Posted 12/20/2018